AMERICAN COLLEGE OF RADIOLOGY ONCOLOGIC IMAGING NETWORK

我们建议组织一个机构合作小组 将组成美国放射学院的个人 肿瘤成像网络（ACROIN）。 ACROIN 将开展临床试验 通过其委员会结构和招聘特设人员 参与者严格评估新兴和更稳定的成像 与癌症患者相关的技术。 最终， Acroin 的目标是： 提高患者生存率；提高质量 通过减少诊断和治疗的侵入性来延长生命；改善 通过更快、更确定的治疗来提高患者的幸福感 诊断和治疗；降低诊断和治疗发病率； 加速将发现转化为临床技术；和速度 将有价值的技术传播到临床实践中。顶叶酸 将通过多种策略来实现这些目标，包括： 关于最重要的恶性肿瘤和技术；适当的混合 新兴技术和成熟技术之间的试验；评估使用 各种终点——从简单的准确性测试到评估 根据成熟度，患者的治疗效果和成本效益 技术；核心与广告之间灵活、基础广泛的协作 临时参与者，包括机构、科学家、行业、付款人、 和患者；建立一个旨在加速 制定和实施试验并加快传播 他们的发现；并依赖过去丰富的经验 总部和生物统计中心高质量开展 临床试验。 ACROIN 建立了广泛的委员会结构 履行其职能；获得 42 家领先企业的承诺 他们将努力将放射科作为核心部门 机构参与者；收到八家合作函 其他合作团体 - 每个团体指定一名代表 去顶酸；并获得多家商业公司的承诺 和保险公司，一旦 ACROIN 推出，他们将参与并支持 成立。

We propose to organize a cooperative group of institutions and individuals that will comprise the American College of Radiology Oncologic Imaging Network (ACROIN). ACROIN will develop clinical trials through its committee structure and the recruitment of ad hoc participants to rigorously assess both emerging and more stable imaging technologies as they relate to patients with cancer. Ultimately, ACROIN's goals are to: increase patient survival; improve quality of life through reduced invasiveness of diagnosis and treatment; improve patients' sense of well-being through greater rapidity and certainty of diagnosis and treatment; reduce diagnostic and therapeutic morbidity; hasten the translation of discovery to clinical technology; and speed the diffusion of worthwhile technologies into clinical practice. ACROIN will accomplish these goals by several strategies, including: a focus on the most important malignancies and technologies; an appropriate mix of trials between emerging and mature technologies; evaluation using a variety of endpoints -from tests of simple accuracy to assessment of patient outcomes and cost-effectiveness, according to the maturity of the technology; flexible, broad-based collaboration between core and ad hoc participants, including institutions, scientists, industry, payors, and patients; establishment of an organization designed to speed the development and implementation of trials and hasten dissemination of their findings; and reliance on the extensive past experience of the Headquarters and Biostatistical Center in conducting high quality clinical trials. ACROIN has developed an extensive committee structure to fulfill its functions; secured the commitment of 42 leading departments of radiology that they will try to qualify as core institutional participants; received letters of collaboration from eight other cooperative groups - each of which has designated a representative to ACROIN; and received the promises of a number of commercial companies and insurers that they will participate in and support ACROIN once it is established.